Abaris Biotechnology Opportunities (UCITS V)

Fund Description

Abaris Biotechnology Opportunities is a small cap biotech fund seeking extraordinary long-term equity returns. The fund invests in a broadly diversified portfolio of early stage biopharma companies with blockbuster potential as well as high growth biotech companies. 

Based on a data driven investment logic the fund complements large cap biopharma and biotech portfolios.   

Key Fund Characteristics


Superior Long-Term Equity Returns

Expected Long-Term Return

20-40% p.a.


High Volatility, >30% p.a.

Market Capitalization Focus

Micro-, Small-, Mid Caps

Equity Positions

50-100 Equities
(Investment Universe: >1,000 Equities)

Sector Allocation

Biotechnology Sector

Portfolio Construction

Long Only Equities

> 7 Years

How the Fund is Different

  • Long-term investment success based on a compelling logic
  • Fundamentally different stock selection process based on the collective investment intelligence of the world’s best biotech investors and the Abaris Fundamental Return Concept
  • The fund combines the most attractive companies from the entire health care sector
  • Diversified portfolio of early stage biopharma companies with blockbuster potential as well as high growth biotech companies that overproportionally benefit from biotechnology mega trends (“pure plays”)
  • Little overlap with other active or passive biotechnology funds by focusing on micro-, small- and mid caps, not mega caps (long runway for growth)

Applied Frameworks


Fundamental Return Concept

Concept to achieve attractive long-term returns, as equity returns are always driven by a company’s fundamental performance in the long-term.

Thus, the Abaris Fundamental Return Concept is the basis of our investment philosophy and applied in all Abaris equity funds.


Collective Investment Intelligence

Systematic analysis leveraging the collective investment intelligence of the world’s best investors by evaluating their equity positions based on mandatory regulatory filings.


The portfolio companies in the Abaris Biotechnology Opportunities fund currently benefit from megatrends, such as:

Genomic Services

Digital Health

Medical Devices

Proteomic Services

Biotechnology Services

Next Gen Cancer Therapies

Share Classes

Request Factsheet

Please enter the value you see in the picture into the field.

* Ranges and average numbers serve as indications and shall not be interpreted as hard investment limits

This website uses only technically necessary cookies.  Privacy Statement  |  Legal Notice  


Visitors of the website of Abaris Investment Management AG ("AIM") agree to the following terms and conditions. Without such declaration of consent, the AIM website may not be visited.

Some of the collective investment schemes named on the AIM website have not yet been authorized by the Swiss Financial Market Supervisory Authority FINMA for distribution in or from Switzerland. Therefore, all related information is exclusively addressed to qualified investors as defined in Art. 10 para. 3 of the Swiss Federal Act on Collective Investment Schemes (CISA).

The AIM Website is not intended for persons who, by reason of their nationality, place of business, residence or other reasons, are subject to any jurisdiction that prohibits the publication of or access to the content of the AIM Website.

Information published on the AIM website does not constitute a recommendation, an offer or a solicitation to buy or sell collective investment schemes, to engage in securities transactions or to conclude any legal transaction. Furthermore, information on the AIM website may neither serve as a basis for any decision-making with regard to any economic, legal, tax or other advisory issues, nor as a basis for investment decisions or other decisions solely on the basis of this information. Consultation with a qualified professional is essential and is hereby explicitly recommended.

The entire content of the AIM website is protected by intellectual property rights. You may download or print out a hard copy of individual pages and/or sections of the AIM website, provided any copyright or other proprietary notices are not removed and remain visible on such copies. All property rights remain with AIM. The complete or partial reproduction, transmission (electronically or by other means), modification, linking or use of the AIM website for public or commercial purposes is prohibited without the prior written consent of AIM.

The information published and opinions expressed on the AIM website are provided by AIM for personal use and informational purposes only and are subject to change without notice. AIM does not guarantee the accuracy, completeness or timeliness of the information and statements on the AIM website. AIM disclaims, without limitation, all liability for any loss or damage of any kind, whether direct, indirect or consequential, which might arise from the use of the AIM website, reliance on any information published on the AIM website, or any links to third-party websites.

Past performance is not indicative of future performance. Potential investors should note that investments may involve substantial risks and the investment value may increase or decrease.

I hereby confirm that I have taken note of the above information, in particular regarding the addressees of this website, and that I agree with the terms of use.